ReNerve Receives $517k R&D Refund
Released
Released
Announcement PDF
+61 (03) 9482 3940
157 Heidelberg Rd,
Northcote, VIC 3070
www.renerve.com.au
Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au
Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au
ASX Announcement
16 February 2026
ReNerve Receives $517k R&D Tax Incentive Refund
ReNerve Limited (ASX, "ReNerve" or "the Company"), an Australian biotechnology company developing innovative
products for peripheral nerve injury ("PNI") repair, is pleased to announce that it has received a $517,133 Research
and Development (R&D) Tax Incentive Refund from the Australian Tax Office under the Federal Government’s R&D
Tax Incentive Scheme.
During the 2024–25 income year, ReNerve continued to progress its portfolio of proprietary biomaterial and
medical device programs focused on peripheral nerve repair and related surgical applications. ReNerve also
advanced complementary projects evaluating novel biomaterials and processes intended to improve surgical
handling, reduce complications such as scarring and infection, and support better functional outcomes for patients
requiring complex nerve and tissue repair procedures.
The R&D Tax Incentive Scheme is an important Australian Government program that encourages companies to
engage in innovative research and development to the benefit of Australia by providing a tax offset for eligible R&D
activities.
The R&D Tax Incentive Refund strengthens ReNerve’s cash position and will primarily be used for ongoing
development of products and supporting its roadmap to commercialisation.
- ENDS -
This announcement has been approved for release by the Company’s Board of Directors.
For further information and enquiries, please contact:
2 | P a g e
About ReNerve Limited (ASX:RNV)
ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical
technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device
company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral
nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients
worldwide.
Proven Clinical Success
ReNerve’s first flagship product, the FDA-cleared NervAlign® Nerve Cuff, is already making a dramatic difference
in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable
results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores
dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant
improvement that's changing lives.
Comparison of Patient Pre & Post Surgery Pain Score
Standard of Care vs NervAlign™ Nerve Cuff Protected Nerve Repairs
The comparison of pain scores between the two cohorts of patients
3.3
0.4
3 | P a g e
Comprehensive Product Portfolio
ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:
On market
• NervAlign® Nerve Cuff – Our bioabsorbable protective wrap, naturally absorbed within six months of
surgery.
• Empliq™ Deep Dermal tissue product -- A unique deep dermal product used in the repair of reconstructive
and cosmetic surgical cases.
• Empliq™ Amniotic tissue product ranges -- Three amniotic tissue product ranges used to aid the healing
of wounds.
In development
• NervAlign® Nerve Conduit Range – Next-generation nerve conduit leveraging advantages of eCOO
technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
• NervAlign® Nerve Guide Matrix – a customised and ready-to-use alternative to existing nerve grafts, for
treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to
undergo additional sural nerve harvesting.
• NervAlign® Bionic Nerve – Next-generation combination technology for the most challenging nerve
repairs.
Market Leadership and Growth
With demonstrated market traction since the Company’s 2022 product launch, ReNerve achieved 53% revenue
growth in FY25, reaching $271k in sales. Our high-margin, scalable products are positioning us as the go-to solution
for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at
US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.1
Vision and Values
We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for
nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's
natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve
surgery.
1
Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)
Share your feedback
Discover